新鲜抗瘤免疫干扰剂GDF-15在多种癌症中的功能特征
Min Fang1,2, Ziyu Wang1, Yuxin Zhou1
1Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, 410219, China.
Scientific reports
|August 22, 2025
概括
增长差异化因子15 (GDF-15) 在不同癌症中表现不同,影响诊断和预后. 这项研究探讨了它在瘤干,基因组不稳定性和免疫透中的作用,强调了GDF-15作为潜在的泛癌生物标志物.
科学领域:
- 癌症学
- 分子生物学
- 生物标志物发现
背景情况:
- 增长差异化因子15 (GDF-15) 涉及各种生物过程,包括癌症.
- 它在广泛的癌症中发挥的具体作用和诊断/预后价值仍需全面阐明.
研究的目的:
- 进行GDF-15表达的综合癌症分析,其诊断意义,以及与临床参数,瘤干,基因组不稳定性和免疫格局的相关性.
- 研究GDF-15在各种癌症的预后价值,包括使用免疫组织化学 (IHC) 验证肺腺癌 (LUAD).
主要方法:
- 使用多个数据库来获得GDF-15表达数据,并使用XIANTAO Academic和Sangerbox进行诊断意义分析.
- 评估了GDF-15表达和临床数据,瘤干,基因组不稳定性和预后之间的关系.
- 研究了分子相互作用,RNA甲基化,免疫细胞透,免疫基因和免疫检查点.
- 对LUAD组织进行基于IHC的组织微阵列分析,以检测蛋白质表达和生存相关性.
主要成果:
- GDF-15在多种癌症类型中表现出差异性表达,BRCA,CHOL,COAD,HNSC,LIHC,LUAD,READ,STAD,THCA和UCEC显著上调,KIRC和LUSC的下调.
- 在CHOL,COAD,ESCC,GBM,LAML,READ和THCA中表现出显著的诊断价值,并在几种癌症中具有预后价值.
- 揭示了GDF-15在瘤干,基因组不稳定性,铁平衡,急性阶段反应和细胞衰老中的作用.
- 证实GDF-15对免疫细胞透,相关基因和免疫检查点的影响.
- 在LUAD中IHC分析显示GDF-15蛋白水平升高与整体存活率降低有关.
结论:
- GDF-15作为潜在的泛癌生物标志物具有显著的诊断和预后价值.
- 它的表达与关键的瘤过程有关,包括干性,基因组不稳定性和免疫调节.
- GDF-15在LUAD蛋白表达中的作用及其与低生存率的关联强调了其临床相关性.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...